Search clinical trials for: Minimal Residual Disease (MRD) positive leukemia

Total 381377 results

Northern Italy Leukemia Group
Associazione Italiana per la Ricerca sul Cancro

Completed

Treatment of Adult ALL With an MRD-directed Programme.

Acute Lymphoblastic Leukemia

Italy
Xianmin Song, MD

Recruiting

Next Generation Sequencing（NGS）Monitors Minimal Residual Disease（MRD）in Allo-PBSCT Patients

NGS Monitor MRD

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... and other collaborators

Completed

MRD-directed Therapy for Low-risk and Intermediate-risk AML.

Acute Myeloid Leukemia | Minimal Residual Disease

China
Cancer Institute and Hospital, Chinese Academy...
Beijing Huanxing Cancer Hospital; Cancer Hospital, Chinese Academy of Medical...

Recruiting

Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer (AMENDER)

Early-stage Breast Cancer

China
Exact Sciences Corporation
NSABP Foundation Inc

Recruiting

CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer (MRD)

Colorectal Cancer

United States
WeiWei Xiao
Haplox Biotechnology Co., Ltd.

Recruiting

Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology

Minimal Residual Disease | Circulating Tumor DNA | Rectal Adenocarcinoma | Neoadjuvant Chemoradiotherapy

China
Rajshekhar Chakraborty, MD
Hope Foundation

Recruiting

Non-invasive MRD Assessment in Multiple Myeloma (NIRVANA)

Myeloma

United States
BAIYONG SHEN
GeneCast Biotechnology Co., Ltd.

Not yet recruiting

ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma

Pancreatic Cancer Resectable

China
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS (FIL_BIOWM)

Waldenstrom Macroglobulinemia

Italy
Prof. Christina Peters
Amgen

Terminated

ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT

Minimal Residual Disease | ALL, Childhood

Norway, Spain, Denmark, Austria, Belgium, Czechia, France, Italy, Poland, Slovakia
Sun Yat-sen University

Recruiting

Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia

China
FengYan Jin

Not yet recruiting

A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment (MRD)

Multiple Myeloma | Minimal Residual Disease
The First Hospital of Jilin University
Geneplus-Beijing Co. Ltd.

Recruiting

Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer

Endometrial Cancer

China
University of Michigan
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Development of a Multifunctional Rehabilitation Device for Persons With Parkinson's Disease

Parkinson Disease

United States
University of Texas Southwestern Medical Center

Not yet recruiting

Clinical Performance Evaluation of the C2i Test

Muscle Invasive Bladder Cancer
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Minimal Residual Disease | AML, Adult
Second Xiangya Hospital of Central South University
Geneplus-Beijing Co. Ltd.

Not yet recruiting

ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy

Non-small Cell Lung Cancer

China
ResMed

Completed

Narval CC Mandibular Repositioning Device in the Second-line Treatment of Severe Obstructive Sleep Apnea Hypopnea (OSAH) (ORCADES)

Obstructive Sleep Apnea Syndrome

France
Therapeutic Advances in Childhood Leukemia Consortium
Genzyme, a Sanofi Company

Terminated

Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

Minimal Residual Disease | Leukemia, Lymphoblastic, Acute | Leukemia, Myelogenous, Acute

United States
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events (MEASURE)

Acute Myeloid Leukemia in Remission

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge

Breast Neoplasms | Nipple Discharge

China
Qilu Hospital of Shandong University
The Affiliated Hospital of Qingdao University; Shandong Provincial Hospital; Jinan... and other collaborators

Recruiting

Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

Stage II-III Gastric Cancer

China
The Children's Hospital of Zhejiang University...

Completed

MRD Detection by NGS in Pediatric B-ALL

Acute Lymphoblastic Leukemia, Pediatric

China
University of Zurich

Completed

Seated Evaluation of Anorectal funcTion by High Resolution Anorectal Manometry (SEAT)

Incontinence | Anismus

Switzerland
First Affiliated Hospital Xi'an Jiaotong University
Second Affiliated Hospital of Xi'an Jiaotong University

Not yet recruiting

MRD Test in Common Risk Stage II Colorectal Cancer (HuaMC-1)

Stage II Colorectal Cancer

China
University of Kansas

Recruiting

HIFT for People With Mobility-Related Disabilities (Research GO)

Physical Disability | Mobility Limitation

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid Leukemia (AML1310)

Acute Myeloid Leukemia

Italy
Stichting European Myeloma Network
Janssen Pharmaceutica

Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS (TAURUS)

Multiple Myeloma

Austria, Greece, Italy, Netherlands, Germany
Guangdong Provincial People's Hospital

Recruiting

MRD Monitoring in Lung Cancer After Resection

Lung Cancer

China
The First Affiliated Hospital of Zhengzhou University
BeiGene

Recruiting

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC (Seagull)

NSCLC

China
Institut Paoli-Calmettes

Unknown

Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment (LLCRlowdoz)

Chronic Lymphocytic Leukemia

France
Guangdong Provincial People's Hospital
Haplox

Not yet recruiting

Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.

Esophageal Squamous Cell Carcinoma | Minimal Residual Disease

China
M.D. Anderson Cancer Center

Suspended

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Colon Cancer | Resected Stage

United States
University of Michigan Rogel Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Multiple Myeloma

United States
Peking University People's Hospital

Recruiting

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Acute Leukemia | MDS | CML | MDS/MPN

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial

Biliary Tract Cancer

China
Novartis Pharmaceuticals
Children's Oncology Group

Recruiting

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA)

B-Cell Acute Lymphoblastic Leukemia

United States, Belgium, Italy, Canada, Sweden, Netherlands, Norway, United Kingdom, Germany, Spain, France, Finland, Denmark
Yanhong Deng

Not yet recruiting

Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) (AFFORD)

Colorectal Cancer
Goethe University

Completed

Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

ALL, Recurrent, Adult

Germany
Fudan University
Shanghai Weihe Medical Laboratory Co., Ltd.

Not yet recruiting

Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach

Pancreatic Ductal Adenocarcinoma

China
University of Ulm

Terminated

Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)

Acute Myeloid Leukemia

Germany
Goethe University
University Hospital Schleswig-Holstein

Recruiting

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

ALL, Recurrent, Adult

Germany
Nordic MDS Group

Unknown

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

MDS | SCT | MRD

Denmark, Norway, Sweden
Helsinki University Central Hospital

Recruiting

Systemic Neoadjuvant and Adjuvant Control by Precision Medicine in Rectal Cancer (SYNCOPE)

Colorectal Cancer

Finland
Guangdong Association of Clinical Trials

Recruiting

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

MRD

China
Boston Medical Center

Completed

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis (MRD)

Amyloidosis

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Completed

Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL

Acute Lymphoblastic Leukemia | MRD-positive

China
Fondazione EMN Italy Onlus

Completed

Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD) (MRD)

Multiple Myeloma

Italy
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

Lymphoblastic Leukemia, Acute, Childhood | Leukemia, Acute Lymphoblastic

United States

Search clinical trials for: Minimal Residual Disease (MRD) positive leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations